Cardio Diagnostics Valuation
| CDIO Stock | USD 4.42 0.27 6.51% |
At this time, the firm appears to be undervalued. Cardio Diagnostics shows a prevailing Real Value of $18.07 per share. The current price of the firm is $4.42. Our model approximates the value of Cardio Diagnostics from analyzing the firm fundamentals such as Current Valuation of (1.87 M), shares owned by insiders of 7.55 %, and Return On Equity of -0.81 as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Cardio Diagnostics' price fluctuation is slightly risky at this time. Calculation of the real value of Cardio Diagnostics is based on 3 months time horizon. Increasing Cardio Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cardio Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cardio Stock. However, Cardio Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.42 | Real 18.07 | Hype 4.49 | Naive 6.62 |
The intrinsic value of Cardio Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cardio Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cardio Diagnostics Holdings helps investors to forecast how Cardio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cardio Diagnostics more accurately as focusing exclusively on Cardio Diagnostics' fundamentals will not take into account other important factors: Cardio Diagnostics Total Value Analysis
Cardio Diagnostics Holdings is currently forecasted to have valuation of (1.87 M) with market capitalization of 7.22 M, debt of 663.1 K, and cash on hands of 9.66 M. The negative valuation of Cardio Diagnostics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Cardio Diagnostics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.87 M) | 7.22 M | 663.1 K | 9.66 M |
Cardio Diagnostics Investor Information
The company has price-to-book (P/B) ratio of 0.63. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cardio Diagnostics recorded a loss per share of 4.34. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 13th of May 2025. Based on the key indicators related to Cardio Diagnostics' liquidity, profitability, solvency, and operating efficiency, Cardio Diagnostics Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Cardio Diagnostics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cardio Diagnostics has an asset utilization ratio of 0.33 percent. This suggests that the Company is making $0.003287 for each dollar of assets. An increasing asset utilization means that Cardio Diagnostics Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Cardio Diagnostics Ownership Allocation
Cardio Diagnostics Holdings shows 7.55 percent of its outstanding shares held by insiders and 4.86 percent owned by other corporate entities.Cardio Diagnostics Profitability Analysis
The company reported the previous year's revenue of 34.89 K. Net Loss for the year was (8.38 M) with profit before overhead, payroll, taxes, and interest of 19.9 K.About Cardio Diagnostics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Cardio Diagnostics Holdings. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cardio Diagnostics based exclusively on its fundamental and basic technical indicators. By analyzing Cardio Diagnostics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Cardio Diagnostics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cardio Diagnostics. We calculate exposure to Cardio Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cardio Diagnostics's related companies.Cardio Diagnostics Inc. develops and manufactures a genetic and epigenetic based test for prevention and detection of cardiovascular disease. Cardio Diagnostics Inc. was founded in 2017 and is based in Chicago, Illinois. Cardio Diagnostics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Cardio Diagnostics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 26.9 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardio Diagnostics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardio Diagnostics. If investors know Cardio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardio Diagnostics is measured differently than its book value, which is the value of Cardio that is recorded on the company's balance sheet. Investors also form their own opinion of Cardio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Cardio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardio Diagnostics' market value can be influenced by many factors that don't directly affect Cardio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardio Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.